Pegylated liposomal doxorubicin (Caelyx®) in metastatic breast cancer: A community-based observation study

Oncology

Volumn 72, Issue 3-4, 2008, Pages 147-151

  Salzberg, Marc ^a   Thürlimann, Beat ^b,g   Hasler, Ursula ^c   Delmore, Geoffrey ^c   Von Rohr, Albert ^d   Thürlimann, Annatina ^b   Ruhstaller, Thomas ^b   Stopatschinskaja, Shanna ^e   Von Moos, Roger ^f  

^a MyoContract   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c Kantonsspital Frauenfeld   (Switzerland)

^d KLINIK HIRSLANDEN   (Switzerland)

^e Essex Chemie AG   (Switzerland)

^f KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^g Senologie Zentrum Ostschweiz   (Switzerland)

Author keywords

Liposomal doxorubicin; Metastatic breast cancer; Pegylated liposomal doxorubicin

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; METHOTREXATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER STAGING; CARDIOTOXICITY; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HAND FOOT SYNDROME; HEALTH SURVEY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SWITZERLAND; THROMBOCYTE COUNT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HEALTH CARE SURVEYS; HUMANS; LIPOSOMES; MIDDLE AGED; NEOPLASM METASTASIS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 38549120799     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112731     Document Type: Article

References (22)

1. Lutz JM, Francisci S, Mugno E, Usel M, Pompe-Kirn V, Coebergh JW, Bieslka-Lasota M; EUROPREVAL Working Group: Cancer prevalence in Central Europe: the EUROPREVAL Study. Ann Oncol 2003;14:313-322.
2. Chia S, Speers C, Kang A, et al: The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population-based cohort. Proc Am Soc Clin Oncol 2003;22:6.
3. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women (review). J Clin Oncol 1998;16:3439-3460.
4. Jones D, Ghersi D, Wilcken N: Addition of drug/s to a chemotherapy regimen for metastatic breast cancer (review). Cochrane Database Syst Rev 2006;3:CD003368.
5. Rivera E: Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003;8(suppl 2):3-9.
6. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
7. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C: Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22:3893-3901.
8. Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA: The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer (review). Semin Oncol 2004;31(suppl 13):106-146.
9. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-436.
10. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999;86:72-78.
11. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-1785.
12. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-1047.
13. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN; National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111.
14. O'Brien ME, Leonard RC, Barrett-Lee PJ, Eggleton SP, Bizzari JP: Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 1999;10:205-210.
15. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24:2773-2778.
16. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997;15:3185-3591.
17. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E: The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006;94:1615-1620.
18. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M: A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006;42:882-887.
19. Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK: Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 1999;18:17-26.
20. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323-328.
21. 2) in platinum/paclitaxel- refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369-372.
22. 2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006;70:141-146.